§ 5026.1. Annual review of all medications and forms of treatment for sickle cell disease
Oklahoma Statutes AnnotatedTitle 63. Public Health and SafetyEffective: November 1, 2022
Effective: November 1, 2022
63 Okl.St.Ann. § 5026.1
§ 5026.1. Annual review of all medications and forms of treatment for sickle cell disease
A. The Oklahoma Health Care Authority shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease. The purpose of the annual review is to determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease, and whether the Authority should seek to add or recommend additional medications, treatments, or services.
2. The extent to which emergency department providers are adequately trained and otherwise prepared to treat and manage sickle cell patients presenting with vaso-occlusive crises including but not limited to the extent to which providers follow clinically validated algorithms and protocols regarding such treatment and management;
E. On or before January 15, 2023, and on or before January 15 each year thereafter, the Authority shall submit a report to the President Pro Tempore of the Senate and the Speaker of the House of Representatives for distribution to the appropriate subject matter committees that details the Authority's findings from the annual review required by this section and any recommendations to the Legislature based upon those findings. The Authority shall publish the annual report required by this subsection to its website in a manner accessible by the general public.
Credits
Laws 2022, c. 162, § 1, eff. Nov. 1, 2022.
63 Okl. St. Ann. § 5026.1, OK ST T. 63 § 5026.1
Current with emergency effective legislation through Chapter 257 of the Second Regular Session of the 59th Legislature (2024). Some sections may be more current, see credits for details.
End of Document |